Increased concentrations of inflammatory mediators in unstable angina: correlation with serum troponin T

A Mazzone, S De Servi, I Mazzucchelli, I Bossi, E Ottini, M Vezzoli, F Meloni, M Lotzinker, G Mariani

Abstract

Objective—To measure plasma interferon γ, monocyte chemotactic protein-1 (MCP-1), and interleukin 6 and to assess their correlation with cardiac troponin T in unstable angina.

Design—Blood sampling in patients undergoing coronary arteriography for known or suspected ischaemic heart disease.

Patients—76 patients divided in three groups: 29 with unstable angina (group 1), 28 with stable angina (group 2), and 19 without ischaemic heart disease and with angiographically normal coronary arteries (group 3).

Main outcome measures—Plasma interleukin 6, interferon γ, MCP-1, and troponin T in the three groups of patients.

Results—Interleukin 6 was increased in group 1 (median 2.19 (range 0.53–50.84) pg/ml compared with the control group (1.62 (0.79–3.98) pg/ml) (p < 0.005), whereas interferon γ was higher in group 1 (range 0–5.51 pg/ml) than in the other two groups (range 0–0.74 pg/ml and 0–0.37 pg/ml; p < 0.005 and p < 0.001, respectively). Patients with unstable angina (group 1) and positive troponin T had higher concentrations of interferon γ than those with negative troponin T (0–5.51 pg/ml vs 0–0.60 pg/ml; p < 0.001). Plasma MCP-1 was also higher in group 1 (median 2.67 (range 0.69–8670) pg/ml) than in the other two groups (1.34 (19–890) pg/ml and 84.5 (5–325) pg/ml; p < 0.005 and p < 0.001, respectively), and among group 1 patients with a positive troponin T assay than in those with normal troponin T (531 (14.5–8670) pg/ml v 69 (6–3333) pg/ml; p < 0.01). There was no difference in plasma interleukin 6 in group 1 patients between those with and without raised troponin T.

Conclusions—The inflammatory cytokines interferon γ and MCP-1 are increased in patients with unstable angina, particularly in those with raised concentrations of troponin T, suggesting that they are probably related to myocardial cell damage or to plaque rupture and thrombus formation.

(Heart 2001;85:571–575)

Keywords: inflammatory cytokines; troponin T; unstable angina

Over the past two decades many experimental and human studies have examined the role of cytokines, chemoattractants, and adhesives molecules in the initiation, progression, and clinical emergence of the atherosclerotic plaque. These observations suggest that, whatever the initial stimuli (mechanical, chemical, infectious, or immunological), a continuous ongoing inflammatory process plays a role in the evolution of an uncomplicated atheromatous plaque into complex and vulnerable atheroma. Hallmarks of this evolving immune process are monocyte-macrophage and lymphocyte cells, initially found in the fatty streaks and then playing a major role in plaque rupture and superimposed thrombosis. In acute coronary syndromes an increase in circulating activated lymphocytes, as well as of activated neutrophils, their inflammatory markers, and monocyte adhesion molecules, has been described. Activated T lymphocytes secrete interferon γ, a cytokine which interferes with the stability of the collagenous framework of the plaque’s fibrous cap. On the one hand interferon γ greatly decreases the synthesis of the interstitial forms of collagen from smooth muscle cells, while on the other hand it stimulates the formation and activation of macrophages, which accelerate the breakdown of both collagen and elastin. Moreover, this cytokine stimulates revascularisation and in situ thrombosis and impairs the ability of the endothelium to generate nitric oxide. Taken together, these processes are likely to affect the evolution of unstable coronary syndromes.
Monocyte chemotactic protein-1 (MCP-1) is a chemokine that is implicated in the adhesiveness and transmigration of monocytes and T lymphocytes into the vessel wall. Several lines of evidence indicate that this chemotactic protein is one of the key factors initiating the inflammatory process of atherogenesis. The expression and release of MCP-1 from the endothelium is induced by multiple chemical stimuli (lipopolysaccharides, cytokines, oxidised low density lipoprotein (LDL)) or by interaction between activated neutrophils, platelets, and endothelial cells. Finally, this chemokine may also activate or increase the expression of adhesion molecules to facilitate monocyte adhesion.25–27

As no study has evaluated the role of interferon γ and MCP-1 in unstable coronary syndromes, we undertook to measure plasma concentrations of interleukin 6, interferon γ, and MCP-1 and to correlate them with troponin T concentrations in patients with both stable and unstable angina.

LABORATORY INVESTIGATION
Aliquots of blood from each patient were collected in test tubes containing EDTA. Plasma was separated by centrifugation and then frozen at −80°C.

Quantitative measurements of interleukin 6 and interferon γ were performed using an enzyme linked immunosorbent assay (ELISA) with a microtitre plate precoated with the specific monoclonal antibody (Bender MedSystem, Vienna, Austria). Tests were performed according to the supplier's instructions. Samples and standards were assayed simultaneously in duplicate. The sample volume used for interleukin 6 and interferon γ was 50 µl. None of the samples was diluted. The standard curve range for interleukin 6 was 1.6–100 pg/ml and for interferon γ, 1.5–100 pg/ml. The sensitivity of the assay was 0.6 pg/ml for interleukin 6 and 0.30 pg/ml for interferon γ. The overall intraassay coefficient of variation was 3.4% for interleukin 6 and 5.7% for interferon γ; the overall interassay coefficients of variation were 5.2% and 5.7%.

Quantitative measurement of MCP-1 was performed by ELISA, using a DuoSet kit (R&D System, Edinburgh, UK) with monoclonal antibodies for capture and detection. Samples and
standards were assayed simultaneously in duplicate. The sample volume used was 50 µl. None of the samples was diluted. The standard curve range was 15.6–1000 pg/ml. The sensitivity of the assay was 3.4 pg/ml. The overall intra-assay and interassay coefficients of variation were 2.9% and 4.8%, respectively.

Serum troponin T was measured by an electrochemiluminescence immunoassay (ECLIA), using the Elesys 2010 system (Roche Diagnostic, Basel, Switzerland). The intra-assay coefficient of variation was 5% and the interassay variability 7%. The lower limit of detection was 0.01 ng/ml and the diagnostic cut-off was 0.1 ng/ml.

The study was approved by the institutional ethics committee for human subjects. Informed consent was obtained from all patients.

STATISTICAL ANALYSIS

Results are expressed as median and range. The non-parametric one way Kruskal–Wallis test was used to investigate differences among the three groups of patients at each time point. The Mann–Whitney test for unpaired data was used for comparison of data between patients with unstable angina and those with stable angina. Two tailed probability values of \( p < 0.05 \) were considered significant.

Results

Clinical and angiographic characteristics of the patients are given in table 1. Interleukin 6 was increased in group 1 (unstable angina) compared with group 3 (control): group 1, mean 2.19 (range 0.53–50.84) pg/ml; group 2, 1.81 (0.66–48.93) pg/ml; group 3, 1.62 (0.79–3.98) pg/ml; \( p < 0.005 \) group 1 \( v \) group 3 (fig 1).

Interferon \( \gamma \) was higher in the group 1 than in the other two groups: group 1, 0 (0–5.51) pg/ml; group 2, 0 (0–0.74) pg/ml; group 3, 0 (0.037) pg/ml; \( p < 0.005 \) and \( p < 0.001 \), respectively (fig 2). Among the 29 patients with unstable angina, 11 with raised troponin T had significantly higher plasma interferon \( \gamma \) than the 18 without a raised troponin T: 0 (0–5.51) pg/ml \( v \) 0 (0–0.60) pg/ml (\( p < 0.001 \)) (fig 3). On the other hand, no difference was found in plasma interleukin 6 concentrations in patients with unstable angina between those with raised and those with normal plasma troponin T: 2.89 (1.04 to 13.56) \( v \) 1.90 (0.53 to 15.84) pg/ml.

Plasma MCP-1 concentrations were also higher in the patients with unstable angina than in those with stable angina or in the controls: group 1, 267 (6–8670) pg/ml; group 2, 134 (19–89) pg/ml; group 3, 84.5 (5–325) pg/ml; \( p < 0.005 \) group 1 \( v \) group 3 (fig 4).

In the patients with unstable angina differences were found in interleukin 6, interferon \( \gamma \), and MCP-1 values depending on whether or
not they had had chest pain in the 48 hours preceding coronary arteriography (table 2).

Discussion

Inflammation is well recognised as a pathogenic component of unstable angina. Interleukin 6, a proinflammatory cytokine with stimulatory effects on T and B lymphocytes, induces the synthesis of acute phase proteins such as C reactive protein and fibrinogen. Biasucci and colleagues found that interleukin 6 was increased in 61% of patients with unstable angina, compared with 21% of patients with stable angina. Increasing concentrations of interleukin 6 were also found to be associated with a complicated clinical course in unstable angina.

Interleukin 6 is the major determinant of the liver production of acute phase proteins through direct stimulation of hepatocytes. Raised concentrations of C reactive protein, a prototypical acute phase reactant, are also associated with an unfavourable outcome. In the TIMI (thrombolysis in myocardial infarction) 11A substudy, the relation between C reactive protein concentrations and the qualitative result of a rapid troponin T assay was determined in 437 patients with unstable angina and non- Q wave myocardial infarction. The probability of a positive rapid troponin T assay was significantly higher in patients with unstable angina in comparison with a control group of patients without coronary artery disease. Although patients with unstable angina had higher values than those with stable angina, the difference between these two groups was not significant. Moreover, in patients with unstable angina no correlation was found between interleukin 6 concentrations and increased troponin T values.

Interleukin 6 is a major chemotactic molecule secreted in the vessel wall, is predominantly found in macrophage-rich areas of atherosclerotic lesions. Gawaz and colleagues studied the secretion of MCP-1 by human umbilical endothelial cells incubated with non-stimulated or ADP activated platelets for six hours. They found that activated platelets induced endothelial secretion of MCP-1, whereas significantly less secretion occurred in the presence of non-stimulated platelets, implying that an activation dependent release of platelet derived products stimulates MCP-1 production, favouring the migration and entrapment of monocytes—an early step in the atherogenesis and restenosis process. In a preliminary report, Nakamura and colleagues measured MCP-1 concentrations in 15 patients with acute myocardial infarction, 30 with stable angina, and 19 controls. These investigators found increased concentrations of this chemotactic protein in patients with acute myocardial infarction compared with the other two groups. As particularly high MCP-1 concentrations were found in patients with preinfarction angina, they concluded that monocytes may play an important role in plaque rupture. In our study, we observed much higher concentrations of MCP-1 in patients with unstable angina than in the other two groups, and a significant correlation with a positive troponin T.

Similarly, interferon γ concentrations were also significantly higher in patients with unstable angina than in the other two groups. Moreover, in the unstable angina group, patients with a positive troponin T assay had higher interferon γ values than those with a negative troponin T. Interferon γ is a potent immunostimulatory cytokine secreted by T lymphocytes, which promotes atherogenesis through local effects in the arterial wall as well as through a systemic effect on plasma lipoproteins. Moreover, this cytokine greatly decreases the ability of human smooth muscle cells to express the interstitial collagen genes and can also contribute to activating the apoptosis programme in human vascular smooth muscle cells. Inhibition of interstitial collagen synthesis and impaired muscle cell growth in the fibrous cap of the atherosclerotic lesion may destabilise vulnerable regions of the plaque, rendering them weak and prone to rupture.

Table 2 Interleukin 6 (IL-6), interferon γ (IFN-γ), and monocyte chemotactic protein-1 (MCP-1) values in patients with unstable angina who did or did not have chest pain in the 48 hours preceding coronary arteriography

<table>
<thead>
<tr>
<th></th>
<th>Chest pain within 48 hours (n=10)</th>
<th>No chest pain within 48 hours (n=19)</th>
</tr>
</thead>
<tbody>
<tr>
<td>IL-6 (pg/ml)</td>
<td>2.83 (2.19–4.23)</td>
<td>2.16 (0.53–50.84)</td>
</tr>
<tr>
<td>IFN-γ (pg/ml)</td>
<td>0 (0–0.47)</td>
<td>0 (0–5.31)</td>
</tr>
<tr>
<td>MCP-1 (pg/ml)</td>
<td>257 (44–1746)</td>
<td>196 (6–8670)</td>
</tr>
</tbody>
</table>

Values are median (range).
significantly reduces the rate of myocardial infarction before as well as during coronary angioplasty in patients with refractory unstable angina and raised troponin T concentrations. It has also been shown that enhanced activation of coagulation is present in patients with troponin T positive unstable angina. Terres and colleagues studied 22 patients with angiographically documented coronary heart disease and unstable angina at rest; in nine patients with increased maximum serum troponin T value, the maximum concentrations of fibrin monomers during the first 48 hours were higher than in patients with persistently normal troponin T. The investigators concluded that enhanced activation of coagulation in patients with troponin T positive unstable angina may contribute to the adverse outcome associated with this condition.

It is possible that the greatly raised concentrations of MCP-1 and interferon γ observed in patients with unstable angina and positive troponin T are secondary to myocardial cell damage. Alternatively, it is conceivable that the increased concentrations of MCP-1 and interferon γ are related to the mechanism of plaque rupture and thrombus formation. Further studies should clarify the time course of MCP-1 and interferon γ concentrations in unstable angina and their prognostic value.

CONCLUSIONS

MCP-1 and interferon γ concentrations are specifically increased in patients with unstable angina, particularly in those with a positive troponin T assay, suggesting a probable relation to myocardial cell damage or plaque rupture with thrombus formation. Further studies should clarify the time course of MCP-1 and interferon γ concentrations in unstable angina and their prognostic value.

23 van der Wai AC, Becker AE, van der Loos CM, et al. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation 1994;89:30–44.
Increased concentrations of inflammatory mediators in unstable angina: correlation with serum troponin T

A Mazzone, S De Servi, I Mazzucchelli, I Bossi, E Ottini, M Vezzoli, F Meloni, M Lotzinker and G Mariani

*Heart* 2001 85: 571-575
doi: 10.1136/heart.85.5.571

Updated information and services can be found at:
[http://heart.bmj.com/content/85/5/571](http://heart.bmj.com/content/85/5/571)

**These include:**

**References**
This article cites 29 articles, 11 of which you can access for free at:
[http://heart.bmj.com/content/85/5/571#BIBL](http://heart.bmj.com/content/85/5/571#BIBL)

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**
Articles on similar topics can be found in the following collections

- Drugs: cardiovascular system (8842)
- Acute coronary syndromes (2742)
- Clinical diagnostic tests (4779)

**Notes**

To request permissions go to:
[http://group.bmj.com/group/rights-licensing/permissions](http://group.bmj.com/group/rights-licensing/permissions)

To order reprints go to:
[http://journals.bmj.com/cgi/reprintform](http://journals.bmj.com/cgi/reprintform)

To subscribe to BMJ go to:
[http://group.bmj.com/subscribe/](http://group.bmj.com/subscribe/)